Jerry L. Morris

481 total citations
14 papers, 365 citations indexed

About

Jerry L. Morris is a scholar working on Neurology, Cognitive Neuroscience and Molecular Biology. According to data from OpenAlex, Jerry L. Morris has authored 14 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 4 papers in Cognitive Neuroscience and 2 papers in Molecular Biology. Recurrent topics in Jerry L. Morris's work include Parkinson's Disease Mechanisms and Treatments (9 papers), Neurological disorders and treatments (6 papers) and Visual perception and processing mechanisms (3 papers). Jerry L. Morris is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (9 papers), Neurological disorders and treatments (6 papers) and Visual perception and processing mechanisms (3 papers). Jerry L. Morris collaborates with scholars based in United States and Canada. Jerry L. Morris's co-authors include J. Thomas Hutton, Jeffrey W. Elias, William C. Koller, Cheryl Waters, Rajesh Pahwa, Gustavo C. Román, Rajesh Varma, Charles H. Adler, M. B. Stern and Robert L. Rodnitzky and has published in prestigious journals such as Neurology, Movement Disorders and CNS Drugs.

In The Last Decade

Jerry L. Morris

14 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jerry L. Morris United States	9	268	72	68	48	47	14	365
Th. M�ller Germany	9	232 0.9×	90 1.3×	79 1.2×	32 0.7×	44 0.9×	10	348
Ariane Park United States	7	252 0.9×	71 1.0×	62 0.9×	82 1.7×	44 0.9×	8	379
M Gonce Belgium	10	174 0.6×	77 1.1×	68 1.0×	27 0.6×	33 0.7×	28	323
Tobias Langheinrich United Kingdom	7	96 0.4×	26 0.4×	50 0.7×	54 1.1×	64 1.4×	11	207
Sandrine Greffard France	5	315 1.2×	134 1.9×	42 0.6×	16 0.3×	46 1.0×	12	394
Mario F. Mendez United States	9	80 0.3×	24 0.3×	142 2.1×	113 2.4×	22 0.5×	16	326
Spiridon Konitsiotis Greece	12	332 1.2×	166 2.3×	56 0.8×	56 1.2×	47 1.0×	31	455
WILLIAM P. ISGREEN United States	7	461 1.7×	158 2.2×	75 1.1×	47 1.0×	33 0.7×	8	576
Toby C. Yaltho United States	9	324 1.2×	118 1.6×	32 0.5×	55 1.1×	23 0.5×	10	389
Silvia Ríos‐Romenets Colombia	5	155 0.6×	46 0.6×	26 0.4×	27 0.6×	28 0.6×	9	221

Countries citing papers authored by Jerry L. Morris

Since Specialization

Citations

This map shows the geographic impact of Jerry L. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry L. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry L. Morris more than expected).

Fields of papers citing papers by Jerry L. Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry L. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry L. Morris. The network helps show where Jerry L. Morris may publish in the future.

Co-authorship network of co-authors of Jerry L. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry L. Morris. A scholar is included among the top collaborators of Jerry L. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry L. Morris. Jerry L. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Hutton, J. Thomas, Leo Verhagen Metman, Thomas N. Chase, et al.. (2001). Transdermal dopaminergic D₂ receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study. Movement Disorders. 16(3). 459–463. 49 indexed citations

Hutton, J. Thomas, Jerry L. Morris, & Jeffrey W. Elias. (1999). Visual contrast sensitivity in Parkinson's disease is worsened with cabergoline treatment. Parkinsonism & Related Disorders. 5(3). 87–91. 4 indexed citations

Hutton, J. Thomas, William C. Koller, J. Eric Ahlskog, et al.. (1996). Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology. 46(4). 1062–1065. 64 indexed citations

Hutton, J. Thomas & Jerry L. Morris. (1994). Therapeutic Advantages of Sustained Release Levodopa Formulations in Parkinsonʼs Disease. CNS Drugs. 2(2). 110–119. 3 indexed citations

Hutton, J. Thomas, Jerry L. Morris, & Jeffrey W. Elias. (1993). Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease. Archives of Neurology. 50(7). 721–724. 69 indexed citations

Hutton, J. Thomas, et al.. (1993). Contrast sensitivity dysfunction in Alzheimer's disease. Neurology. 43(11). 2328–2328. 37 indexed citations

Hutton, J. Thomas, et al.. (1993). Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology. 43(3_part_1). 613–613. 31 indexed citations

Hutton, J. Thomas & Jerry L. Morris. (1992). Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.. PubMed. 42(1 Suppl 1). 51–6; discussion 57. 19 indexed citations

Hutton, J. Thomas, et al.. (1992). Contrast sensitivity in PD. Neurology. 42(5). 1126–1126. 3 indexed citations

10.

Hutton, J. Thomas & Jerry L. Morris. (1991). Long-Term Evaluation of Sinemet® CR in Parkinsonian Patients with Motor Fluctuations. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 18(4). 467–471. 3 indexed citations

11.

Hutton, J. Thomas, et al.. (1991). Spatial contrast sensitivity is reduced in bilateral Parkinson's disease. Neurology. 41(8). 1200–1200. 27 indexed citations

12.

Hutton, J. Thomas, et al.. (1989). Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.. PubMed. 39(11 Suppl 2). 67–72; discussion 72. 25 indexed citations

13.

Hutton, J. Thomas, et al.. (1988). Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa. Archives of Neurology. 45(8). 861–864. 30 indexed citations

14.

Morris, Jerry L. & Andrew St. Martin. (1981). Job enrichment and the mentally retarded worker. International Journal of Rehabilitation Research. 4(2). 217–217. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact